Should I Buy GYRE? GYRE 2026 Analysis

Should You Buy Gyre Therapeutics Inc (GYRE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

7.880

1 Day change

4.93%

52 Week Range

13.750

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient entry: momentum is still weakening (MACD histogram below zero and deteriorating) and price is sitting just above near-term support.
Bullish lean from options open interest (low put/call), but options are extremely illiquid today (0 volume), so sentiment is low-confidence.
Fundamentals (latest quarter) look improved, but without near-term catalysts/news and with weak technicals, the risk/reward for buying immediately isn’t compelling.
Intellectia Proprietary Trading Signals
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock today.

Technical Analysis

Trend/Momentum: Bearish-to-neutral short-term; MACD histogram is negative (-0.00614) and negatively expanding, implying downside momentum is increasing.
RSI (6): 39.37, leaning weak (not deeply oversold), suggesting sellers still have control but a bounce is possible if support holds.
Moving averages: Converging MAs = no clear trend confirmation; typically a “wait for breakout/breakdown” setup.
Key levels: Pivot 7.995 (needs reclaim to improve short-term setup). Support S1 7.696 then S2 7.511; Resistance R1 8.293 then R2 8.478.
Near-term pattern stats: Similar-pattern read suggests a 70% chance of a ~+3.77% move next day, but current momentum indicators don’t strongly support chasing an entry immediately.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Open interest: Calls 109 vs Puts 38 (OI put/call 0.35) = positioning skews bullish.
Liquidity/sentiment quality: Today’s options volume is 0 (no prints), so the put/call volume ratio provides little actionable sentiment.
Volatility: 30D IV ~290% vs historical vol ~69% (very elevated), indicating the market is pricing large moves; IV rank ~67.6 and IV percentile ~56.1 = elevated but not at extreme highs.

Technical Summary

Sell

Buy

Positive Catalysts

and reclaims the pivot (7.995), a quick mean-reversion bounce toward 8.29 becomes more plausible.

Neutral/Negative Catalysts

fails, next support at S2 (7.
implies additional near-term downside.

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $30.56M, +19.92% YoY (solid top-line growth).
Net income: $3.61M, +221.17% YoY (profitability improved sharply).
EPS: $0.03, +200% YoY (earnings trend improving).
Gross margin: 94.67%, -1.63% YoY (slight margin compression, but still extremely high in absolute terms).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating changes or price target updates were provided in the dataset, so there’s no observable recent Street trend to confirm bullish or bearish conviction.
Wall Street pros/cons view (from available data only):
- Pros: improving growth and profitability in 2025/Q3.
- Cons: lacking current catalysts/news and technicals are not supportive for an immediate entry.
Influential/political trading: No recent congress trading data available; hedge funds and insiders show neutral recent activity.

2 Analyst Rating

Wall Street analysts forecast GYRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GYRE is 19 USD with a low forecast of 18 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 7.510

Low

Averages

High

Current: 7.510

Low

Averages

High

H.C. Wainwright

initiated

$18

AI Analysis

2025-08-26

Reason